Dr Herve Avet-Loiseau, presenting at the IV International Workshop on Myeloma Genetics, Pharmacogenomics & Novel Therapeutics, talks about the use of genomic testing to predict survival rates of myeloma patients and to predict which patients will benefit from which drugs. He also talks about types of genomic testing such as FISH (fluorescence in situ hybridisation).

The workshop was supported by an unrestricted medical education grant from the following companies; Celgene, Bristol Myers Squibb, Johnson and Johnson, Takeda Millennium, Novartis Oncology, Cephalon and Onyx Pharmaceuticals.